Replimune Shares Surge After Early Data From Pretreated Melanoma Patients

  • Replimune Group Inc REPL announced initial data from the first 75 patients from the anti-PD1 failed cutaneous melanoma cohort of the IGNYTE clinical evaluating RP1 (vusolimogene oderparepvec) combined with Bristol-Myers Squibb Co's BMY Opdivo (nivolumab). 
  • The overall response rate (ORR) was 36%, and the complete response (CR) rate was 20% compared to the 12.5% shown in the prior 16 patients presented in June 2022. 
  • Safety data with RP1 + nivolumab continues to demonstrate an attractive safety profile, with predominantly ‘on target' Grade 1-2 side effects indicative of systemic immune activation.
  • The Company also provided new data from the ongoing Phase 1 clinical trial evaluating RP2 and RP3, demonstrating promising early signals in metastatic tumors and multiple soft tissue sarcomas.
  • Concurrently, Replimune announced a clinical trial and supply agreement for its RP2/3 program in colorectal cancer (CRC) and hepatocellular carcinoma (HCC) with Roche Holdings AG RHHBY
  • Specifically, the companies will collaborate in third-line (3L) CRC and first- and second-line (1L & 2L) HCC. 
  • Under the terms of the agreement, the companies will share costs, and Roche will supply its currently approved drugs, atezolizumab, and bevacizumab.
  • Replimune remains on track to initiate its Phase 2 development program with RP2/3 in the first half of 2023. 
  • Price Action: REPL shares are up 16.10% at $21.94 on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLarge CapNewsHealth CareContractsSmall CapMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!